- Record: found
- Abstract: found
- Article: not found
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz
1 ,
Louis Fehrenbacher ,
William Novotny ,
Thomas Cartwright ,
John Hainsworth ,
William Heim ,
Jordan Berlin ,
Ari Baron ,
Susan Griffing ,
Eric Holmgren ,
Napoleone Ferrara ,
Gwen Fyfe ,
Beth Rogers ,
Robert Ross ,
Fairooz Kabbinavar
Jun 03 2004
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy.